Harvest Portfolios Group Inc. Sells 11,259 Shares of AbbVie Inc. $ABBV

Harvest Portfolios Group Inc. reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 3.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 285,569 shares of the company’s stock after selling 11,259 shares during the quarter. AbbVie accounts for approximately 1.2% of Harvest Portfolios Group Inc.’s portfolio, making the stock its 17th largest position. Harvest Portfolios Group Inc.’s holdings in AbbVie were worth $66,121,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Norges Bank bought a new position in shares of AbbVie in the 2nd quarter worth $4,288,200,000. Laurel Wealth Advisors LLC lifted its stake in AbbVie by 18,384.4% in the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after buying an additional 5,675,095 shares during the period. Vanguard Group Inc. boosted its holdings in AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after buying an additional 3,380,842 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of AbbVie by 169.3% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock worth $876,662,000 after buying an additional 2,969,202 shares during the period. Finally, Raymond James Financial Inc. grew its position in shares of AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after buying an additional 2,753,312 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Up 3.1%

ABBV stock opened at $231.69 on Friday. The stock has a 50-day moving average price of $224.34 and a two-hundred day moving average price of $222.94. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The stock has a market cap of $409.66 billion, a PE ratio of 98.17, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Insider Activity

In other news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.25% of the stock is owned by company insiders.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: RBC Capital Markets initiated coverage with an Outperform rating and a $260 price target, arguing AbbVie’s growth is durable and the shares have been punished by short‑term competitive concerns — a bullish analyst catalyst that likely supported buying interest. RBC Launches AbbVie Coverage
• Positive Sentiment: The U.S. Justice Department publicly backed AbbVie’s challenge to Colorado’s 340B guidance, giving the company federal support in a case that could affect how discounts are applied and future margin outcomes in that program. DOJ backs AbbVie in 340B fight
• Positive Sentiment: Federal agencies also supported AbbVie’s position in Colorado in separate coverage, reinforcing regulatory/legal momentum in the company’s favor that could protect 340B economics if courts rule similarly. Feds back AbbVie in Colorado 340B fight
• Positive Sentiment: AbbVie received FDA approval for a first‑in‑class, all‑oral fixed‑duration regimen for untreated CLL and announced a $380M U.S. manufacturing buildout to support neuroscience and obesity programs — both add to medium‑term revenue and capacity upside. AbbVie’s CLL Breakthrough And US$380m Build Out
• Positive Sentiment: AbbVie reported fresh real‑world/post‑marketing data updates for upadacitinib (Rinvoq) in teens with eczema — data investors should watch for uptake and label/market expansion implications for a key growth franchise. Upadacitinib Study in Teens
• Neutral Sentiment: Zacks highlights AbbVie as a top long‑term value stock based on style scores — a framing piece that supports a buy thesis but doesn’t present new company‑specific catalysts. Why AbbVie is a Top Value Stock
• Neutral Sentiment: Dividend and longer‑term outlook pieces (Seeking Alpha / Motley Fool) reiterate AbbVie’s income profile and buy‑and‑hold case, helpful context for income investors but unlikely to trigger near‑term moves alone. Health Care Q4 Dividend Roundup
• Negative Sentiment: A Tennessee court rejected AbbVie’s challenge to that state’s contract‑pharmacy law, a loss that keeps legal/regulatory uncertainty around 340B implementation and potential margin headwinds in some states. AbbVie Loses Challenge in Tennessee

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday. DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research note on Tuesday, November 4th. BMO Capital Markets reissued an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research note on Thursday, January 15th. Finally, Evercore lowered their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.